Neridronic acid

Drug Profile

Neridronic acid

Alternative Names: AHDP; AHHexBP; Aminohexane diphosphonate; Attila; Neridronate; Nerixia

Latest Information Update: 03 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Istituto Gentili
  • Developer Abiogen Pharma; Austin Pain Associates; Grunenthal; Lees Pharmaceutical Holdings; Shire Pharmaceuticals Group
  • Class Bisphosphonates; Calcium regulators; Small molecules
  • Mechanism of Action Bone resorption factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Reflex sympathetic dystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Osteitis deformans; Osteogenesis imperfecta
  • Registered Complex regional pain syndromes
  • Discontinued Malignant hypercalcaemia; Postmenopausal osteoporosis

Most Recent Events

  • 16 Dec 2016 Neridronic acid receives Breakthrough Therapy status for Complex regional pain syndrome in USA
  • 01 Dec 2016 Phase-III clinical trials in Complex regional pain syndrome in USA (IV) (NCT02972359)
  • 21 Nov 2016 Grunenthal plans a phase III trial for Complex regional pain syndrome in USA (NCT02972359)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top